References
- Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, Ahn MS, Hahan SM, Gamson J, Russo A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic. Arch Biochem Biophys 1991; 289: 62–70
- Soule BP, Hyodo F, Matsumoto K-I, Simone NL, Cook JA, Krishna MC, Mitchell JB. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007; 42: 1632–1650
- Mitchell J, Xavier S, DeLuca AV, Sowers AL, Cook JA, Krishna MC, Hahan SM, Russo A. A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med 2003; 34: 93–102
- Schubert R, Erker L, Darlow C, Yakushij H, Larson D, Russo A, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant Tempol in Atm-deficient mice. Hum Mol 2004; 13: 1793–1802
- Gueven N, Luff J, Peng C, Hosokawa K, Bottle SE, Lavin MF. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med 2006; 41: 992–1000
- Sui S, Mitchell JB, Samuni A, Mueller S, Kasid U. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice. Cancer 2005; 103: 1302–1313
- Gariboldi MB, Terni F, Ravizza R, Maschini S, Marra M, Condello M, Arancia G, Monti E. The nitroxide Tempol modulates anthracycline resistance in breast cancer cells. Free Radic Biol Med 2006; 40: 1409–1418
- Cotrim AP, Hyodo F, Matsumoto K-I, Sowers AL, Cook JA, Baum BJ, Krishna MC, Mitchell JB. Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res 2007; 13: 4928–4933
- Erker L, Schubert R, Yakushiji H, Barlow C, Larson D, Mitchell J. Cancer chemoprotection by the antioxidant Tempol acts partially via the p53 tumor suppressor. Human Molec Genet 2005; 14: 1699–1708
- Kaledin VI, Nikolin VP, Ageeva TA, Timofeeva OA, Filipenko ML, Ronichevskaya GM, Morozkova TS, Popova NA, Baymak TYu. Cyclophosphamide-induced apoptosis of mouse lymphosarcoma cells in vivo. Voprosi Onkologii 2000; 46: 588–593
- Kaledin VI, Nikolin VP, Baymak TYu, Galyamova MP, Popova NA, Andreeva EM. Effect of phenobarbital on anticancer action of cyclophosphamide depending on the type of induced tumor cells death. Bull Exp Biol Med 2003; 135: 334–338
- Hahn SM, DeLuka AM, Coffin D, Krishna CM, Mitchell JB. In vivo radioprotection and effects on blood pressure of the stable free radical nitroxides. Int J Radiat Oncol Biol Phys 1998; 42: 839–842
- Vasiliou V, Marselos M. Tissue distribution of inducible aldehyde dehydrogenase activity in the rat after treatment with phenobarbital or methylcholanthrene. Pharmacol Toxicol 1989; 64: 39–42
- Deitrich RA, Bludeau P, Poper M, Schmuck J. Induction of aldehyde dehydrogenase. Biochem Pharmacol 1978; 27: 2343–2347
- Karmeli F, Eliakim R, Okon E, Samuni A, Rachmilewitz D. A stable nitroxide radical effectively decreases mucosal damage in experimental colitis. Gut 1995; 37: 386–393
- Sladek NE. Anticancer drugs: Reactive metabolism and drug interactions. Pergamon Press, London 1994
- Sladek NE. Clinically relevant resistance in cancer chemotherapy. Kluwer Academic Publishers, Boston; Dordrecht; London 2002
- Patel JM. Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther 1990; 47: 137–146
- Fraiser L, Kehrer JP. Effect of indomethacin, aspirin, nordihydroguairetic acid, and piperonyl butoxide on cyclophosphamide-induced bladder damage. Drug Chem Toxicol 1993; 16: 117–133
- Hipkens JH, Struck RF, Gurtoo HL. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res 1981; 41: 3571–3583
- Sladek NE, Kollander R, Sreerama L, Klang DT. Cellular levels of aldehyde dehydrogenase (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002; 49: 309–321
- Kaledin VI, Nikolin VP, Popova NA. Cyanamide promotes the antitumor effect of cyclophosphamide more than its toxic effect. Doklady Biol Sci 2008; 420: 568–570
- Pustylnyak VO, Shirshova AN, Gulyaeva LF, Kaledin VI, Nikolin VP, Kaurova GI, Matalin VA, Shmakov AG, Shvartsberg VM, Korobeynichev OP. Hyperinduction of CYP2B and CYP2C in mouse liver by the products of tributylphosphate electrochemical fluorination. Bull SB RAMS 2005; 118: 79–84